References
- Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000;101:329–35
- Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545–56
- Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005;186:1–20
- Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013;31:2094–102
- Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010;4:290–4
- Kolla V, Robertson NM, Litwack G. Identification of a mineralocorticoid/glucocorticoid response element in the human Na/K ATPase alpha1 gene promoter. Biochem Biophys Res Commun 1999;266:5–14
- Huyet J, Pinon GM, Fay MR, et al. Structural determinants of ligand binding to the mineralocorticoid receptor. Mol Cell Endocrinol 2012;350:87–95
- Derfoul A, Robertson NM, Lingrel JB, et al. Regulation of the human Na/K-ATPase beta1 gene promoter by mineralocorticoid and glucocorticoid receptors. J Biol Chem 1998;273:20702–11
- Kopec W, Loubet B, Poulsen H, Khandelia H. Molecular mechanism of Na(+), K(+)-ATPase malfunction in mutations characteristic of adrenal hypertension. Biochemistry 2014;53:746–54
- Schmitz B, Nedele J, Guske K, et al. Soluble adenylyl cyclase in vascular endothelium: gene expression control of epithelial sodium channel-alpha, Na+/K+-ATPase-alpha/beta, and mineralocorticoid receptor. Hypertension 2014;63:753–61
- Zhao F, Wang L, Liu K. In vitro anti-inflammatory effects of Arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J Ethnopharmacol 2009;122:457–62
- Xu Z, Wang X, Zhou M, et al. The antidiabetic activity of total lignan from Fructus Arctii against alloxan-induced diabetes in mice and rats. Phytother Res 2008;22:97–101
- Cho MK, Jang YP, Kim YC, Kim SG. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition. Int Immunopharmacol 2004;4:1419–29
- Awale S, Lu J, Kalauni SK, et al. Identification of Arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 2006;66:1751–7
- Zhu Z, Yan J, Jiang W, et al. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. J Neurosci 2013;33:13138–49
- Shen X, Tomoo K, Uchiyama S, et al. Structural and thermodynamic behavior of eukaryotic initiation factor 4E in supramolecular formation with 4E-binding protein 1 and mRNA cap analogue, studied by spectroscopic methods. Chem Pharm Bull (Tokyo) 2001;49:1299–303
- Ikeda U, Hyman R, Smith TW, Medford RM. Aldosterone-mediated regulation of Na+, K(+)-ATPase gene expression in adult and neonatal rat cardiocytes. J Biol Chem 1991;266:12058–66
- Skou JC, Esmann M. The Na,K-ATPase. J Bioenerg Biomembr 1992;24:249–61
- Funder JW. The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opin Investig Drugs 2003;12:1963–9
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17